5.4% NephrAmine® (Essential Amino Acid Injection) is indicated for adult and pediatric use, in conjunction with other measures, to provide nutritional support for uremic patients, particularly when oral nutrition is infeasible or impractical. See WARNINGS , PRECAUTIONS, Pediatric Use , Special Precautions in Pediatric Patients , and DOSAGE AND ADMINISTRATION .
The objective of nutritional management of renal decompensation is the provision of sufficient amino acid and caloric support for protein synthesis without greatly exceeding the renal capacity to excrete metabolic wastes. Three grams of nitrogen per day provided as essential amino acids with adequate calories produce nitrogen equilibrium in many stable patients with chronic uremia. Although nitrogen requirements m...
www.bbraun.comProtect from light until use.
5.4% NephrAmine® (Essential Amino Acid Injection) is a sterile, nonpyrogenic solution containing crystalline essential amino acids plus histidine. Each 250 mL unit provides Rose's recommended daily intake of essential amino acids1 plus 625 mg of histidine, considered essential for uremics. The total nitrogen content of a 250 mL unit is approximately 1.6 grams (10 g of protein equivalent) in 14 grams of amino acids. All amino acids designated USP are the "L" isomer.
Each 100 mL contains:
Histidine USP2..............................................0.25 g
Isoleucine USP..............................................0.56 g
Leucine USP.................................................0.88 g
Lysine...........................................................0.64 g
(added as Lysine Acetate USP....................0.90 g)
Methionine USP............................................0.88 g
Phenylalanine USP.........................................0.88 g
Threonine USP..............................................0.40 g
Tryptophan USP...........................................0.20 g
Valine USP....................................................0.64 g
Cysteine....................................................<0.014 g
(as Cysteine HCl•H2O USP....................<0.020 g)
Sodium Bisulfite (as an antioxidant)..............<0.05 g
Water for Injection USP......................................qs
pH adjusted with Sodium Hydroxide NF as required.
pH: 6.5 (6.0–7.0); Calculated Osmolarity: 435 mOsmol/liter
Total Nitrogen: Approx. 0.65 g/100 mL
Concentration of Electrolytes (mEq/liter): Sodium 5
Chloride <3; Acetate Approx. 44
NephrAmine® provides an intravenously compatible mixture of essential amino acids which, when infused with hypertonic dextrose as a source of calories, plus electrolytes, minerals, and vitamins, provides in a small volume of fluid all ingredients (with the exception of essential fatty acids) needed for total parenteral nutrition in patients with renal disease.
Infusion of NephrAmine® and hypertonic dextrose provides essential amino acids and calories for protein synthesis to promote improved cellular metabolic balance. Infusion of these components can decrease the rate of rise of blood urea nitrogen and minimize deterioration of serum potassium, magnesium, and phosphorus balance in patients with impaired renal function. The extent to which essential amino acids and calories promote incorporation of waste urea nitrogen into newly synthesized amino acids in man, as it does in experimental animals, is, so far, not established.
The accelerated decrease in serum creatinine levels seen in patients with limited extra-renal complications suggests that treatment with NephrAmine® and hypertonic dextrose leads to earlier return of renal function in patients with potentially reversible acute renal failure. By providing nutritional support and promoting biochemical improvement as well as earlier return of renal function, NephrAmine® and hypertonic dextrose decrease morbidity associated with acute renal failure.
It is thought that acetate from lysine acetate, under the condition of parenteral nutrition, does not impact net acid-base balance when renal and respiratory functions are normal. Clinical evidence seems to support this thinking; however, confirmatory experimental evidence is not available.
The amounts of sodium and chloride present are not of clinical significance.
5.4% NephrAmine® (Essential Amino Acid Injection) is indicated for adult and pediatric use, in conjunction with other measures, to provide nutritional support for uremic patients, particularly when oral nutrition is infeasible or impractical. See WARNINGS, PRECAUTIONS, Pediatric Use, Special Precautions in Pediatric Patients, and DOSAGE AND ADMINISTRATION.
NephrAmine® is contraindicated in patients with severe, uncorrected electrolyte and acid-base imbalance, hyperammonemia, decreased (subcritical) circulating blood volume, inborn errors of amino acid metabolism, or hypersensitivity to one or more amino acids present in the solution.
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
This product contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
Safe and effective use of central venous nutrition requires a knowledge of nutrition as well as clinical expertise in recognition and treatment of the complications which can occur. Frequent clinical evaluation and laboratory determinations are necessary for proper monitoring of central venous nutrition. Laboratory tests should include measurement of blood sugar, electrolyte, and serum protein concentrations; kidney and liver function tests; and evaluation of acid-base balance and fluid balance. Other laboratory tests may be suggested by the patient's condition.
NephrAmine® does not replace dialysis and conventional supportive therapy in patients with renal failure.
Administration of NephrAmine® to pediatric patients, especially in high dose ranges, may result in hyperammonemia. Administration of NephrAmine® to infants, particularly neonates and low birth weight infants, may result in elevated plasma amino acid levels (e.g., hypermethionemia) and hyperammonemia. In these very young age groups, amino acid formulations developed specifically for nutritional support of infants and pediatric patients, should be considered.
Clinically significant hypokalemia, hypophosphatemia, or hypomagnesemia may occur as a result of therapy with NephrAmine® and hypertonic dextrose and replacement therapy may become necessary.
Administration of nitrogen in any form to patients with marked hepatic insufficiency or hepatic coma may result in plasma amino acid imbalances, hyperammonemia, or central nervous system deterioration. NephrAmine® should, therefore, be used with caution in such patients.
The intravenous administration of these solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the solute concentration of the solution infused. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the concentration of the solution.
Conservative doses of amino acids should be given, dictated by the nutritional status of the patient.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Significant deviations from normal concentrations may require the use of additional electrolyte supplements.
In order to promote urea nitrogen reutilization in patients with renal failure, it is essential to provide adequate calories with minimal amounts of the essential amino acids, and to severely restrict the intake of nonessential nitrogen. Hypertonic dextrose solutions are a convenient and metabolically effective source of concentrated calories.
Fluid balance must be carefully monitored in patients with renal failure and care should be taken to avoid circulatory overload, particularly in association with cardiac insufficiency.
In patients with myocardial infarct, infusion of amino acids should always be accompanied by dextrose, since in anoxia, free fatty acids cannot be utilized by the myocardium, and energy must be produced anaerobically from glycogen or glucose.
Strongly hypertonic nutrient solutions should be administered through an indwelling intravenous catheter with the tip located in the superior vena cava.
Special care must be taken when giving hypertonic dextrose to glucose-intolerant patients such as diabetic or prediabetic and uremic patients, especially when the latter are receiving peritoneal dialysis. To prevent severe hyperglycemia in such patients, insulin may be required.
Administration of glucose at a rate exceeding the patient's utilization may lead to hyperglycemia, coma, and death.
Administration of amino acids without carbohydrates may result in the accumulation of ketone bodies in the blood. Correction of this ketonemia may be achieved by the administration of carbohydrates.
Abrupt cessation of hypertonic dextrose infusion may result in rebound hypoglycemia.
When 5.4% NephrAmine® (Essential Amino Acid Injection) is subjected to changes in temperature, there is a chance that some transient crystallization of amino acids may occur. Thorough shaking of the bottle for about one minute should redissolve the amino acids. If the amino acids do not completely redissolve, the bottle must be rejected.
To minimize the risk of possible incompatibilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration, and periodically during administration.
Use only if solution is clear and vacuum is present.
Drug product contains no more than 25 µg/L of aluminum.
Frequent clinical evaluation and laboratory determinations are necessary for proper monitoring during administration.
Laboratory tests should include measurement of blood sugar, electrolyte, and serum protein concentrations, kidney and liver function tests, and evaluation of acid-base balance and fluid balance. Other laboratory tests may be suggested by the patient's condition.
Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.
No in vitro or in vivo carcinogenesis, mutagenesis, or fertility studies have been conducted with 5.4% NephrAmine® (Essential Amino Acid Injection).
Animal reproduction studies have not been conducted with 5.4% NephrAmine® (Essential Amino Acid Injection). It is also not known whether NephrAmine® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. NephrAmine® should be given to a pregnant woman only if clearly needed.
Information is unknown.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NephrAmine® is administered to a nursing woman.
Safety and effectiveness of amino acid injections in pediatric patients have not been established by adequate and well-controlled studies. However, the use of amino acid injections in pediatric patients as an adjunct in the offsetting of nitrogen loss or in the treatment of negative nitrogen balance is well established in the medical literature. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L). See INDICATIONS AND USAGE, WARNINGS, and DOSAGE AND ADMINISTRATION.
NephrAmine® has not been studied in geriatric patients. Elderly patients are known to be more prone to fluid overload and electrolyte imbalance than younger patients. This may be related to impairment of renal function which is more frequent in an elderly population. As a result the need for careful monitoring of fluid and electrolyte therapy is greater in the elderly. All patients, including the elderly, require an individual dose of all parenteral nutrition products to be determined by the physician on an individual case-by-case basis, which will be based on body weight, clinical condition and the results of laboratory monitoring tests. There is no specific geriatric dose.
See WARNINGS.
Administration by central venous catheter should be used only by those familiar with this technique and its complications.
Central venous nutrition may be associated with complications which can be prevented or minimized by careful attention to all aspects of the procedure including solution preparation, administration, and patient monitoring. It is essential that a carefully prepared protocol, based on current medical practices, be followed, preferably by an experienced team.
Although a detailed discussion of the complications of central venous nutrition is beyond the scope of this insert, the following summary lists those based on current literature:
The placement of a central venous catheter should be regarded as a surgical procedure. One should be fully acquainted with various techniques of catheter insertion as well as recognition and treatment of complications. For details of techniques and placement sites, consult the medical literature. X-ray is the best means of verifying catheter placement. Complications known to occur from the placement of central venous catheters are pneumothorax, hemothorax, hydrothorax, artery puncture and transection, injury to the brachial plexus, malposition of the catheter, formation of arterio-venous fistula, phlebitis, thrombosis, and air and catheter embolus.
The constant risk of sepsis is present during central venous nutrition. Since contaminated solutions and infusion catheters are potential sources of infection, it is imperative that the preparation of parenteral nutrition solutions and the placement and care of catheters be accomplished under controlled aseptic conditions.
Parenteral nutrition solutions should ideally be prepared in the hospital pharmacy under a laminar flow hood. The key factor in their preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and subsequent admixtures.
Parenteral nutrition solutions should be used promptly after mixing. Any storage should be under refrigeration for as brief a time as possible. Administration time for a single bottle and set should never exceed 24 hours.
Consult the medical literature for a discussion of the management of sepsis during central venous nutrition. In brief, typical management includes replacing the solution being administered with a fresh container and set, and the remaining contents are cultured for bacterial or fungal contamination. If sepsis persists and another source of infection is not identified, the catheter is removed, the proximal tip cultured, and a new catheter reinserted when the fever has subsided. Nonspecific, prophylactic antibiotic treatment is not recommended. Clinical experience indicates that the catheter is likely to be the prime source of infection as opposed to aseptically prepared and properly stored solutions.
The following metabolic complications have been reported: metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia and glycosuria, osmotic diuresis and dehydration, rebound hypoglycemia, elevated liver enzymes, hypo- and hypervitaminosis, electrolyte imbalances, and elevated plasma amino acid levels and hyperammonemia in infants and pediatric patients. Frequent clinical evaluation and laboratory determinations are necessary, especially during the first few days of central venous nutrition, to prevent or minimize these complications.
Frequent laboratory studies are necessary in patients with renal insufficiency due to underlying metabolic abnormalities. Hyperglycemia, a frequent complication, may not be reflected by glycosuria in renal failure. Blood glucose, therefore, must be determined frequently, often every six hours to guide dosage of dextrose and insulin if required.
Serum concentrations of potassium, phosphorus, and magnesium may dramatically decline with successful treatment, individually or together; these substances should be supplemented as required. Special care must be taken to avoid hypokalemia in digitalized patients, or those with cardiac arrhythmias.
5.4% NephrAmine® (Essential Amino Acid Injection) should be used with special caution in pediatric patients, due to limited clinical experience.
Laboratory and clinical monitoring of pediatric patients, especially when nutritionally depleted, must be extensive and frequent. Initial total daily dose should be low, and increased slowly. Dosage of NephrAmine® above one gram of essential amino acids per kilogram body weight per day is not recommended.
For infants, especially neonates and low birth weight infants, amino acid formulations developed specifically for nutritional support of infants and pediatric patients should be considered. If NephrAmine® is administered to these very young patients, extra caution in frequent monitoring of plasma amino acid levels and serum ammonia is strongly recommended.
Frequent monitoring of blood glucose is required in neonates, low birth-weight, or septic infants as infusion of hypertonic dextrose carries a greater risk of hyperglycemia in such patients.
The absence of arginine in NephrAmine® may accentuate the risk of hyperammonemia in infants.
In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).
See WARNINGS and Special Precautions for Central Venous Nutrition.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis, and hypervolemia.
Symptoms may result from an excess or deficit of one or more of the ions present in the solution infused, therefore, frequent monitoring of electrolyte levels is essential.
Infrequent instances of hyperammonemia have been reported following administration of essential amino acid solutions to patients with massive gastrointestinal hemorrhage, nonuremic infants and pediatric patients or following administration of higher than recommended doses to adult or pediatric patients. Elevated plasma amino acid levels (hypermethionemia) have also been reported in infants especially in higher dosage ranges. Elevated serum ammonia levels, plasma amino acid levels, and clinical symptoms may subside when the infusions are discontinued.
Phosphorus deficiency may lead to impaired tissue oxygenation and acute hemolytic anemia. Relative to calcium, excessive phosphorus intake can precipitate hypocalcemia with cramps, tetany, and muscular hyperexcitability.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
In the event of a fluid or solute overload during parenteral therapy, reevaluate the patient's condition and institute appropriate corrective treatment.
The objective of nutritional management of renal decompensation is the provision of sufficient amino acid and caloric support for protein synthesis without greatly exceeding the renal capacity to excrete metabolic wastes.
Three grams of nitrogen per day provided as essential amino acids with adequate calories produce nitrogen equilibrium in many stable patients with chronic uremia. Although nitrogen requirements may be higher in stressed or acutely uremic patients, or those on dialysis, provision of additional nitrogen may not be possible due to fluid intake limits or glucose intolerance.
The usual methods of determining individual patient requirements for amino acids such as nitrogen balance or daily body weight are difficult to perform or interpret in the uremic patient. Therefore, dosage is guided by the patient's fluid intake limits and glucose and nitrogen tolerances, as well as metabolic and clinical response. Rate of rise of blood urea nitrogen generally diminishes with infusion of essential amino acids. However, excessive intake of dietary protein or increased protein catabolism may alter this response.
Generally, 250 to 500 mL of 5.4% NephrAmine® (Essential Amino Acid Injection), containing approximately 1.6 to 3.2 grams of nitrogen (in 13.4 to 26.8 grams of essential amino acids), are given daily. Adequate calories should be provided simultaneously. Each 250 mL of NephrAmine® is typically mixed aseptically with 500 mL of 70% dextrose to yield a solution of 1.8% NephrAmine® in 47% dextrose. This mixture provides a calorie-to-nitrogen ratio of 744:1.
Solution administrated by peripheral vein should not exceed twice normal serum osmolarity (718 mOsmol/L).
Initial total daily dose should be low and increased slowly. As the dose is increased, frequent laboratory and clinical monitoring is strongly recommended, especially in very young patients, to avoid clinically significant elevations of serum ammonia and plasma amino acid levels. Dosage of NephrAmine® above one gram of essential amino acids per kg of body weight per day is not recommended. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).
Use of 5.4% NephrAmine® in pediatric patients is governed by the same considerations that affect the use of any amino acid solution in pediatrics. The amount administered is dosed on the basis of grams of amino acids/kg of body weight/day.
See INDICATIONS AND USAGE, WARNINGS, PRECAUTIONS, Pediatric Use, and Special Precautions in Pediatric Patients.
Fat emulsion coadministration should be considered when prolonged (more than 5 days) parenteral nutrition is required in order to prevent essential fatty acid deficiency (E.F.A.D.). Serum lipids should be monitored for evidence of E.F.A.D. in patients maintained on fat free TPN.
Electrolyte supplementation may be required. Undiluted NephrAmine® (Essential Amino Acid Injection) contains 5 mEq/liter of sodium. Elevated serum potassium, phosphorus, and magnesium levels generally decrease during treatment with NephrAmine®. Although these effects are beneficial, especially in acute renal failure, in some instances the reduction may be so great that supplementation of these electrolytes is required, especially in the presence of cardiac arrhythmias or digitalis toxicity. During periods of anuria or oliguria, electrolyte supplementation should be done with caution, even if serum levels are in the low normal range.
Compatibility of electrolyte additives to the 5.4% NephrAmine®/hypertonic dextrose mixture must be considered, and potentially incompatible ions such as calcium and phosphate may be added to alternate infusion bottles to avoid precipitation. In patients with hyperchloremic or other metabolic acidosis, sodium and potassium may be added as acetate or lactate salts to provide bicarbonate precursor. The electrolyte content of NephrAmine® must be considered when calculating daily electrolyte intake. Serum electrolytes, including magnesium and phosphorus, should be monitored frequently.
If a patient's nutritional intake is primarily parenteral, vitamins, especially the water soluble vitamins, should also be provided.
Hypertonic mixtures of essential amino acids and dextrose may be safely administered by continuous infusion through a central venous catheter with the tip located in the superior vena cava. Initial infusion rates should be slow, generally 20–30 mL/hour. Increases by increments of 10 mL/hour each 24 hours are recommended to a maximum of 60–100 mL/hour. If administration rate should fall behind schedule, no attempt to "catch up" to planned intake should be made.
Administration rate is governed by the patient's nitrogen, fluid, and glucose tolerance. Uremic patients are frequently glucose intolerant, especially in association with peritoneal dialysis, and may require the administration of exogenous insulin to prevent hyperglycemia. Blood glucose levels must be determined frequently. To prevent rebound hypoglycemia, a solution containing 5% dextrose should be administered when hypertonic dextrose infusions are abruptly discontinued.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Care must be taken to avoid incompatible admixtures. Consult with pharmacist.
5.4% NephrAmine® (Essential Amino Acid Injection) is supplied sterile and nonpyrogenic in glass containers with solid stoppers packaged 12 per case.
NDC REF Size
5.4% NephrAmine®
(Essential Amino Acid Injection)
(Canada DIN 02029464)
0264-1909-55 S9092-SS 250 mL
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.
Protect from light until use.
Rx only
Revised: December 2014
NephrAmine is a registered trademark of B. Braun Medical Inc.
Designed for use with a vented set. Use 18 to 22 gauge needle size for admixing or withdrawing solutions from the glass bottle.
B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862www.bbraun.com
In Canada, distributed by:
B. Braun of Canada, Ltd.
Scarborough, Ontario M1H 2W4
Y36-002-860 LD-450-1
5.4% NephrAmine®
(Essential Amino Acid Injection)
REF S9092-SS
NDC 0264-1909-55
DIN 02029464
HK 22620
250 mL
Protect from light until use.
Each 100 mL contains: Histidine USP* 0.25 g; Isoleucine USP 0.56 g
Leucine USP 0.88 g; Lysine 0.64 g (added as Lysine Acetate USP
0.90 g); Methionine USP 0.88 g; Phenylalanine USP 0.88 g
Threonine USP 0.40 g; Tryptophan USP 0.20 g; Valine USP 0.64 g
Cysteine <0.014 g (as Cysteine HCl•H2O USP <0.020 g)
*See Package Insert.
B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862www.bbraun.com
Sodium Bisulfite (antioxidant) <0.05 g
Water for Injection USP qs
pH adjusted with Sodium Hydroxide NF as required.
pH: 6.5 (6.0-7.0)
Calc. Osmolarity: 435 mOsmol/liter
Electrolytes (mEq/liter):
Sodium 5; Chloride <3
Acetate Approx. 44
Sterile, nonpyrogenic. Single dose container.
For intravenous use only. Use only if solution is clear
and vacuum is present.
Recommended Storage:
Room temperature (25°C). Avoid excessive heat.
Protect from freezing. See Package Insert.
Rx only
NephrAmine is a registered trademark
of B. Braun Medical Inc.
In Canada, distributed by:
B. Braun of Canada, Ltd.
Scarborough, Ontario M1H 2W4
Y37-002-483 LD-393-2
5.4% NephrAmine®
(Essential Amino Acid Injection)
REF S9092-SS
NDC 0264-1909-55
DIN 02029464
HK 22620
250 mL
Protect from light until use.
Each 100 mL contains:
Histidine USP* 0.25 g; Isoleucine USP 0.56 g
Leucine USP 0.88 g; Lysine 0.64 g (added as Lysine
Acetate USP 0.90 g); Methionine USP 0.88 g
Phenylalanine USP 0.88 g; Threonine USP 0.40 g
Tryptophan USP 0.20 g; Valine USP 0.64 g; Cysteine
<0.014 g (as Cysteine HCl•H2O USP <0.020 g)
Sodium Bisulfite (antioxidant) <0.05 g
Water for Injection USP qs
pH adjusted with Sodium Hydroxide NF as required.
pH: 6.5 (6.0-7.0)
Calculated Osmolarity: 435 mOsmol/liter
Electrolytes (mEq/liter):
Sodium 5; Chloride <3; Acetate Approx. 44
*See Package Insert.
See adjacent panel for further product information.
Sterile, nonpyrogenic. Single dose container.
For intravenous use only. Use only if solution is clear
and vacuum is present.
Recommended Storage:
Room temperature (25°C). Avoid excessive heat.
Protect from freezing. See Package Insert.
Rx only
NephrAmine is a registered trademark of B. Braun
Medical Inc.
B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862www.bbraun.com
In Canada, distributed by:
B. Braun of Canada, Ltd.
Scarborough, Ontario M1H 2W4
X12-002-475 LD-199-3
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0264-1909-55 | ML - Milliliter | 0264-1909 | c76a8dfd-2112-42a6-a4a1-e5fc597a530f | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CYSTEINE HYDROCHLORIDE | ACTIVE INGREDIENT | ZT934N0X4W | 8 | |
| HISTIDINE | ACTIVE INGREDIENT | 4QD397987E | 8 | |
| ISOLEUCINE | ACTIVE INGREDIENT | 04Y7590D77 | 8 | |
| LEUCINE | ACTIVE INGREDIENT | GMW67QNF9C | 8 | |
| LYSINE ACETATE | ACTIVE INGREDIENT | TTL6G7LIWZ | 8 | |
| METHIONINE | ACTIVE INGREDIENT | AE28F7PNPL | 8 | |
| PHENYLALANINE | ACTIVE INGREDIENT | 47E5O17Y3R | 8 | |
| THREONINE | ACTIVE INGREDIENT | 2ZD004190S | 8 | |
| TRYPTOPHAN | ACTIVE INGREDIENT | 8DUH1N11BX | 8 | |
| VALINE | ACTIVE INGREDIENT | HG18B9YRS7 | 8 | |
| CYSTEINE | ACTIVE MOIETY | K848JZ4886 | 8 | |
| HISTIDINE | ACTIVE MOIETY | 4QD397987E | 8 | |
| ISOLEUCINE | ACTIVE MOIETY | 04Y7590D77 | 8 | |
| LEUCINE | ACTIVE MOIETY | GMW67QNF9C | 8 | |
| LYSINE | ACTIVE MOIETY | K3Z4F929H6 | 8 | |
| METHIONINE | ACTIVE MOIETY | AE28F7PNPL | 8 | |
| PHENYLALANINE | ACTIVE MOIETY | 47E5O17Y3R | 8 | |
| THREONINE | ACTIVE MOIETY | 2ZD004190S | 8 | |
| TRYPTOPHAN | ACTIVE MOIETY | 8DUH1N11BX | 8 | |
| VALINE | ACTIVE MOIETY | HG18B9YRS7 | 8 | |
| SODIUM BISULFITE | INACTIVE INGREDIENT | TZX5469Z6I | 8 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 8 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0264-1909 | 0264-1909-55 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HISTIDINE | 4QD397987E | ACTIB |
| ISOLEUCINE | 04Y7590D77 | ACTIB |
| LEUCINE | GMW67QNF9C | ACTIB |
| LYSINE ACETATE | TTL6G7LIWZ | ACTIM |
| METHIONINE | AE28F7PNPL | ACTIB |
| PHENYLALANINE | 47E5O17Y3R | ACTIB |
| THREONINE | 2ZD004190S | ACTIB |
| TRYPTOPHAN | 8DUH1N11BX | ACTIB |
| VALINE | HG18B9YRS7 | ACTIB |
| CYSTEINE HYDROCHLORIDE | ZT934N0X4W | ACTIM |
| WATER | 059QF0KO0R | IACT |
| SODIUM BISULFITE | TZX5469Z6I | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | CREAM / TOPICAL | 0.3 %w/w | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / INTRALESIONAL | 0.32 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | TABLET / SUBLINGUAL | 0.5 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / INTRAVENOUS | 96 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SUSPENSION / AURICULAR (OTIC) | NA | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SYRUP / ORAL | NA | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION, SUSPENSION / SOFT TISSUE | 1 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / INTRACARDIAC | 0.1 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 51.8 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | LIQUID / RESPIRATORY (INHALATION) | 0.3 %w/w | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INHALANT / RESPIRATORY (INHALATION) | NA | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | POWDER, FOR SOLUTION / TOPICAL | 0.1 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / INTRAPERITONEAL | 0.66 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / SUBCUTANEOUS | 0.22 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SOLUTION / ORAL | 1 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SOLUTION / TOPICAL | 0.06 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SOLUTION/ DROPS / OPHTHALMIC | 0.1 %w/w | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SUSPENSION / ORAL | 5 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION, SOLUTION / INTRAVENOUS | 0.05 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / IRRIGATION | 0.66 %w/w | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SOLUTION / IONTOPHORESIS | 0.06 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SOLUTION / AURICULAR (OTIC) | 0.08 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / INTRAMUSCULAR | 96 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SOLUTION / RESPIRATORY (INHALATION) | 0.3 %w/w | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION, SUSPENSION / INTRA-ARTICULAR | 1 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | CONCENTRATE / ORAL | 0.5 mg/1ml | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | TABLET / ORAL | 9 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 51.8 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / INTRA-ARTICULAR | 0.32 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SOLUTION / OPHTHALMIC | 0.1 %w/w | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / SOFT TISSUE | 0.1 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | SUSPENSION/ DROPS / OPHTHALMIC | 0.06 %w/w | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | CAPSULE / ORAL | 0.36 mg | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | INJECTION / INTRASYNOVIAL | 0.32 %w/v | ||
| SODIUM BISULFITE | SODIUM BISULFITE | TZX5469Z6I | DROPS / OPHTHALMIC | 0.06 %w/w |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N017766-001 | NEPHRAMINE 5.4% | AMINO ACIDS | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | N017766-001 | NEPHRAMINE 5.4% | 5.4% (5.4GM/100ML) | INJECTABLE / INJECTION | Approved before 1982 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| b09fa614-49bc-4e34-b29a-a04f8dd2ee4a | b924dbf2-5400-4036-941e-487d2ddbb5c4 | 2021-04-07 | Warnings, Adverse reactions | b924dbf2-5400-4036-941e-487d2ddbb5c4 |
Adverse event summaries are temporarily unavailable. Other product information remains available.